SCHEMBL4367045

SCHEMBL4367045

NCCCCC(N)c1ccnc2cc(Cl)ccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FERMT2 Q96AC1 4/20 0.56
NR4A2 P43354 3/20 0.49
SOS2 Q07890 1/20 0.49
CYP1A2 P05177 1/20 0.48
CCR1 P32246 1/20 0.46
CHRM1 P11229 2/20 0.40
KCNH2 Q12809 2/20 0.40
PDE3A Q14432 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
CYP3A4 P08684 1/20 0.40
DRD3 P35462 1/20 0.40
OPRK1 P41145 1/20 0.40
PDE4D Q08499 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
PRNP P04156 1/20 0.40
APP P05067 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL902310 0.96 FERMT2 (0.56) FERMT2NR4A2SOS2CYP1A2CCR1
SCHEMBL4365534 0.91 FERMT2 (0.55) FERMT2NR4A2SOS2CYP1A2CCR1
SCHEMBL5275609 0.84 NR4A2 (0.56) FERMT2NR4A2SOS2CYP1A2CCR1
SCHEMBL4374933 0.83 NR4A2 (0.46) FERMT2NR4A2SOS2CYP1A2CCR1
SCHEMBL4374938 0.82 CCR1 (0.49) FERMT2NR4A2SOS2CYP1A2CCR1
SCHEMBL6661654 0.82 NR4A2 (0.50) FERMT2NR4A2SOS2CYP1A2CCR1
SCHEMBL29625389 0.82 NR4A2 (0.50) FERMT2NR4A2SOS2CYP1A2CCR1
SCHEMBL4374931 0.81 FERMT2 (0.52) FERMT2NR4A2SOS2CYP1A2CCR1
SCHEMBL8909568 0.80 ADRB2 (0.41) FERMT2
SCHEMBL8907641 0.80 LOXL2 (0.49) FERMT2CYP1A2TDP1CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307276-B2 Layer configuration comprising an electron-blocking element AGFA-GEVAERT (BE) 2007-12-11 US claimed
US-7056600-B2 Layer configuration comprising an electron-blocking element AGFA GEVAERT (BE) 2006-06-06 US claimed
US-6977390-B2 Layer configuration comprising an electron-blocking element AGFA GEVAERT (BE) 2005-12-20 US claimed
US-20040040594-A1 Layer configuration comprising an electron-blocking element AGFA-GEVAERT (BE) 2004-03-04 US claimed
US-20040044214-A1 Layer configuration comprising an electron-blocking element AGFA-GEVAERT (BE) 2004-03-04 US claimed
US-20040036067-A1 Layer configuration comprising an electron-blocking element AGFA-GEVAERT (BE) 2004-02-26 US claimed
US-9458376-B2 Electrochromic iptycenes POLISHAK BRENT M (US) 2016-10-04 US disclosed
US-20160137914-A1 ELECTROCHROMIC IPTYCENES POLISHAK BRENT M (US) 2016-05-19 US disclosed
WO-2009148659-A2 ANTIMALARIAL QUINOLINES AND METHODS OF USE THEREOF GEORGETOWN UNIVERSITY (US) 2009-12-10 WO disclosed
US-20090266991-A1 METHOD OF AUTHENTICATING TAGGED POLYMERS SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2009-10-29 US disclosed
EP-1820193-B1 METHOD OF AUTHENTICATING TAGGED POLYMERS SABIC INNOVATIVE PLASTICS IP (NL) 2009-04-22 EP disclosed
US-7307276-B2 Layer configuration comprising an electron-blocking element AGFA-GEVAERT (BE) 2007-12-11 US disclosed
US-7307276-B2 Layer configuration comprising an electron-blocking element AGFA-GEVAERT (BE) 2007-12-11 US disclosed
WO-2004019347-A1 LAYER CONFIGURATION COMPRISING AN ELECTRON-BLOCKING ELEMENT AGFA-GEVAERT (BE) 2004-03-04 WO disclosed
US-20040036067-A1 Layer configuration comprising an electron-blocking element AGFA-GEVAERT (BE) 2004-02-26 US disclosed
US-20030189749-A1 ELECTROCHROMIC-NANOPARTICLE DISPLAYS E INK CORPORATION (US) 2003-10-09 US disclosed
US-6580545-B2 Electrochromic-nanoparticle displays E INK CORPORATION 2003-06-17 US disclosed
WO-2002086611-A1 ELECTROCHROMIC-NANOPARTICLE DISPLAYS E INK CORPORATION (US) 2002-10-31 WO disclosed
US-20020154382-A1 Electrochromic-nanoparticle displays E INK CORPORATION 2002-10-24 US disclosed
WO-1997048705-A1 POTASSIUM CHANNEL BLOCKERS UNIVERSITY COLLEGE LONDON (GB) 1997-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044214-A1 Layer configuration comprising an electron-blocking element PCBP1, RER1, SCO2 FERMT2 2335/4885NR4A2 154/4885SOS2 1272/4885
US-20160137914-A1 ELECTROCHROMIC IPTYCENES IDH3A, EYA2, IDH2 FERMT2 2563/4885NR4A2 2341/4885SOS2 1545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.